Karo Intressenter AB publishes supplement to offer document regarding its public cash offer to the shareholders in Karo Pharma Aktiebolag
On 29 October 2018, EQT VIII[1] (“EQT VIII”), through Karo Intressenter AB[2] (“Karo Intressenter”), announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (”Karo Pharma”) to acquire all outstanding shares[3] in Karo Pharma (the ”Offer”). On 12 November 2018, an offer document regarding the Offer was made public. On 2 January 2019, it was announced that Karo Intressenter had decided to increase the price in the Offer to 38.00 in cash per share. As a consequence thereof, Karo Intressenter has prepared a supplement to the